Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2005

View Archived Issues

Dosing begins in first phase I study for obesity compound oleoyl estrone

Benitec and Garven Institute to develop drugs for diabetes and obesity

Yamanouchi and Nippon Kayaku sign license agreement for Gelpart

Further studies planned to investigate Alferon N for avian flu

First patient treated in acute spinal cord injury study of Cethrin

A phase II study shows effective glycemic control with Basulin in type 1 diabetes

Update on the pharmacokinetics and safety of Virulizin in pancreatic cancer

Higher plasma ghrelin levels found in schizophrenics after olanzapine therapy

New River reviews pipeline progress

Recent progress at Migenix

Phase I/II study to evaluate Onconase in refractory NSCLC

Quark Biotech licenses BT-16 to Sanwa Kagaku Kenkyusho

Enrollment under way in confirmatory phase IIb study of DP-b99 in acute stroke

NovaDel initiates pilot study of lingual spray formulation of ondansetron

Medtronic and Alnylam to develop treatments for neurodegenerative disorders

IND approval allows initiation of phase I trials for PGX-100

Melatonin analogue ML-23 reverses experimental Parkinson's disease in marmosets

Irbesartan plus lipoic acid improves endothelial function of patients with metabolic syndrome

SSR-149415 exerts antidepressant-like effects through vasopressin V1b receptors in lateral septum

Antitumor indenoindole derivative S-36888 cures mice with C38 colon adenocarcinoma

First data on the efficacy of androgen antagonists in bulimia nervosa

Role for the NO-NSAID HCT-1026 in the control of microglia activation

Beth Israel claims imatinib mesylate/rapamycin combination for vascular stenosis and restenosis

Novel anticoagulant agents discovered at Lilly

New tyrosine kinase inhibitors identified at Boehringer Ingelheim

Abbott presents new dopamine D3 modulators for schizophrenia

Novel protein tyrosine kinase inhibitors and their use as anticancer agents

Anti-CD3 monoclonal antibodies with reduced immunogenicity claimed by Alexion

Novel PARP-1 inhibitors described by Altana Pharma in recent patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...